



Hua Medicine
華領醫藥

**Hua Medicine (2552.HK) 2019 Annual Results
Investor Presentation**

Hua Medicine (the “Company”, stock code: 2552.HK) cordially invites you or your representative to attend the online investor presentation in relation to its 2019 annual results on 17 March 2020 (Tuesday).

At the presentation, the management will discuss the Company's 2019 annual results, latest operational developments and business outlook.

Details of the investor presentation are as follows:

Date:	17 March 2020 (Tuesday)
Start time:	9:30 AM Hong Kong Time / Beijing Time
Webcasting portal:	https://services.choruscall.com/links/hua200316.html
Conference call:	<p>Hong Kong Toll Free: 800-905945</p> <p>Hong Kong Local Toll: 852-301-84992</p> <p>Mainland China Toll Free: 4001-201203</p> <p>UK Toll Free: 08002799489</p> <p>International Toll Free: 1-888-346-8982</p> <p>International Toll: 1-412-902-4272</p>
Passcode:	Please state “Hua Medicine” when you have reached an operator

**The presentation will be conducted in English. There will be a Q&A session.*

Please log on the system 10 minutes prior to the start time

For confirmation, please RSVP to huamedicine@icaasia.com by 12 March 2020 (Thursday).

About Hua Medicine

Hua Medicine is a leading, clinical-stage innovative drug development company in China focused on developing novel therapies for the treatment of diabetes. Founded by an experienced group of entrepreneurs and international investment firms, Hua advanced a first-in-class oral drug for the treatment of type 2 diabetes into NDA-enabling stage and is currently evaluating the therapy in adults with diabetes in two Phase III trials in China and in two Phase I trials in the United States. Dorzagliatin has achieved its first primary endpoint in a Phase III monotherapy trial. The company has also initiated product life-cycle management studies of this novel diabetes therapy and advanced its use in personalized diabetes care. Hua Medicine's strategy is to leverage the cost-efficient and high-quality drug development capabilities available in China, while working closely with disease experts and regulatory agencies in China and across the world to advance diabetes care solutions for patients worldwide.